Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Cut to $903.00 by Analysts at BMO Capital Markets

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target lowered by BMO Capital Markets from $950.00 to $903.00 in a research report sent to investors on Tuesday. BMO Capital Markets currently has an overweight rating on the biopharmaceutical company’s stock.

A number of other research firms have also recently commented on REGN. Wells Fargo & Company dropped their price objective on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating for the company in a research report on Friday, January 10th. Canaccord Genuity Group initiated coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price objective for the company. Truist Financial decreased their target price on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating on the stock in a research report on Wednesday, January 8th. Morgan Stanley lowered their target price on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating for the company in a research note on Friday, November 1st. Finally, StockNews.com lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 4th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $983.65.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ:REGN opened at $697.05 on Tuesday. Regeneron Pharmaceuticals has a 12 month low of $642.00 and a 12 month high of $1,211.20. The firm has a market capitalization of $76.60 billion, a price-to-earnings ratio of 17.25, a price-to-earnings-growth ratio of 1.60 and a beta of 0.08. The business’s 50 day simple moving average is $719.16 and its 200-day simple moving average is $918.90. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 33.61% and a return on equity of 16.88%. The business had revenue of $3.79 billion for the quarter, compared to analyst estimates of $3.76 billion. During the same period in the previous year, the firm earned $11.86 EPS. The business’s revenue for the quarter was up 10.3% compared to the same quarter last year. As a group, equities analysts forecast that Regeneron Pharmaceuticals will post 37.75 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th will be given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.50%.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Hedge funds have recently bought and sold shares of the company. Mizuho Securities USA LLC raised its position in shares of Regeneron Pharmaceuticals by 625.5% during the 3rd quarter. Mizuho Securities USA LLC now owns 59,341 shares of the biopharmaceutical company’s stock valued at $62,382,000 after acquiring an additional 51,162 shares in the last quarter. Principal Financial Group Inc. boosted its holdings in shares of Regeneron Pharmaceuticals by 1.7% in the 3rd quarter. Principal Financial Group Inc. now owns 173,092 shares of the biopharmaceutical company’s stock valued at $181,961,000 after buying an additional 2,828 shares during the period. Simplify Asset Management Inc. boosted its holdings in shares of Regeneron Pharmaceuticals by 50.8% in the 3rd quarter. Simplify Asset Management Inc. now owns 9,591 shares of the biopharmaceutical company’s stock valued at $10,082,000 after buying an additional 3,231 shares during the period. Catalytic Wealth RIA LLC bought a new position in shares of Regeneron Pharmaceuticals during the third quarter valued at approximately $1,334,000. Finally, Golden State Equity Partners lifted its holdings in shares of Regeneron Pharmaceuticals by 1,479.1% in the 4th quarter. Golden State Equity Partners now owns 1,358 shares of the biopharmaceutical company’s stock worth $967,000 after purchasing an additional 1,272 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.